Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation

We demonstrate an increase in 1-year bleeding rates in patients with atrial fibrillation and thrombocytopenia on oral anticoagulation Our findings suggest that baseline platelet counts are an important biomarker for hemorrhagic outcomes in atrial fibrillation Whether thrombocytopenia substantively increases the risk of hemorrhage associated with anticoagulation in patients with atrial fibrillation (AF) is not established. The purpose of this study was to compare rates of bleeding in patients with AF and thrombocytopenia (platelet count 150,000/μL). We performed a propensity score-matched, retrospective cohort study of adults (n=1,070) with a new diagnosis of AF who received a prescription for an oral anticoagulant between 2015 and 2020. The thrombocytopenia cohort was defined as having at least two platelet counts on separate days